JAZZ (Jazz Pharmaceuticals) Short Percentage of Float


JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $237.51
GF Value $151.08
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

JAZZ vs BBIO, EXEL, IONS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jazz Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Short Percentage of Float falls into.


JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $237.51 is trading 57.2% above its estimated GF Value™ of $151.08. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Short Percentage of Float:
  • GF Value™: $151.08 vs. price of $237.51 (57.2% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$237.51
Price
$151.08
GF Value